Michael P Bevilacqua

USPTO Granted Patents = 18 (Patent Applications = 10)

CIPO Patents = 3

EPO Patents = 6 (Patent Applications = 3)

Average Co-Inventor Count = 3.4

ph-index = 9

Forward Citations = 659(Granted Patents)

Location History:

San Diego, CA (US) (1996)
Carlsbad, CA (US) (2022)
Boulder, CO (US) (1998 - 2024)

Company Filing History:

Source Precision Medicine, Inc.

patents

4 out of 15,475

University of California

Life Technologies Corporation

patents

where one patent can have more than one assignee

Years Active: 1996-2025

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12268722 - Compositions and uses of locally-applied antimicrobial synthetic cationic polypeptide(s) with enhanced performance and safety (2025-04-08),

2. 12016898 - Compositions and uses of antimicrobial materials with tissue-compatible properties (2024-06-25),

3. 11298401 - Compositions and uses of antimicrobial materials with tissue-compatible properties (2022-04-12),

4. 11285189 - Compositions and uses of locally-applied antimicrobial synthetic cationic polypeptide(s) with enhanced performance and safety (2022-03-29),

5. 10448634 - Composition with high antimicrobial activity and low toxicity (2019-10-22),

6. 9446090 - Compositions and uses of antimicrobial materials with tissue-compatible properties (2016-09-20),

7. 9017730 - Compositions and uses of materials with high antimicrobial activity and low toxicity (2015-04-28),

8. 8718946 - Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles (2014-05-06),

9. 8055452 - Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles (2011-11-08),

10. 7957909 - Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles (2011-06-07),

11. 6964850 - Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles (2005-11-15),

12. 6960439 - Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles (2005-11-01),

13. 6733753 - Composition and method for treating inflammatory diseases (2004-05-11),

14. 6692916 - Systems and methods for characterizing a biological condition or agent using precision gene expression profiles (2004-02-17),

15. 6294170 - Composition and method for treating inflammatory diseases (2001-09-25),

Title: Michael P. Bevilacqua: A Pioneer in Antimicrobial Innovations

Introduction

Michael P. Bevilacqua, based in Boulder, CO, has made significant contributions to the field of antimicrobial research and development. With 18 patents to his name, he is recognized for innovating pharmaceutical compositions that enhance safety and effectiveness in treating infections.

Latest Patents

Among his latest patents, Michael has developed compositions and uses of locally-applied antimicrobial synthetic cationic polypeptides with enhanced performance and safety. These antimicrobial pharmaceutical compositions are formulated to enable local application in vivo, ensuring that doses provide antimicrobial effectiveness while minimizing the risk of local tissue toxicities as well as systemic or distant organ toxicities. Another notable patent includes compositions and uses of antimicrobial materials with tissue-compatible properties. This invention features a mixture of an antimicrobial cationic polypeptide with a second pharmaceutically acceptable polymer, offering methods for treating and preventing infections that may occur when natural barriers of defense are compromised.

Career Highlights

Throughout his career, Michael has worked with several prominent companies, including Amicrobe, Inc. and Source Precision Medicine, Inc. His expertise in antimicrobial formulations has positioned him as a key player in the pharmaceutical industry.

Collaborations

Michael P. Bevilacqua has also collaborated with distinguished professionals in his field, including John C. Cheronis and Victor Tryon. These collaborations further emphasize his commitment to advancing antimicrobial technologies and improving patient care.

Conclusion

Michael P. Bevilacqua’s innovative contributions to antimicrobial research have resulted in significant advancements in the treatment of infections. His patents not only reflect his expertise but also highlight the potential for safer and more effective therapeutic options in the future. Through his work, he continues to inspire and lead the way in antimicrobial innovation.

This text is generated by artificial intelligence and may not be accurate.